Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · IEX Real-Time Price · USD
3.925
+0.105 (2.75%)
At close: Apr 26, 2024, 3:54 PM
3.900
-0.025 (-0.64%)
After-hours: Apr 26, 2024, 4:00 PM EDT
Company Description
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States.
Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jun 30, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Lewis H. Bender M.A., M.B.A., M.S. |
Contact Details
Address: 61 Wilton Road, 3rd Floor Westport, Connecticut 06880 United States | |
| Phone | 203-221-7381 |
| Website | intensitytherapeutics.com |
Stock Details
| Ticker Symbol | INTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001567264 |
| CUSIP Number | 45812M104 |
| ISIN Number | US45828J1034 |
| Employer ID | 46-1488089 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lewis H. Bender M.A., M.B.A., M.S. | Founder, President, Chief Executive Officer and Chairman of the Board |
| John Wesolowski CPA, M.B.A. | Principal Accounting Officer and Controller |
| James M. Ahlers | Executive Vice President of Corporate Finance |
| Joseph Talamo CPA, M.B.A. | Chief Financial Officer |
| Brian Schwartz M.D. | Executive Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | 8-K | Current Report |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 14, 2024 | 10-K | Annual Report |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | 8-K | Current Report |
| Dec 12, 2023 | 8-K | Current Report |
| Nov 22, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |
| Sep 5, 2023 | 8-K | Current Report |